You might want to take a look at Bausch + Lomb Corporation (BLCO) now

Bausch + Lomb Corporation (NYSE: BLCO) stock fell -2.77% on Wednesday to $18.60 against a previous-day closing price of $19.13. With 0.68 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.39 million shares. During the session, the Medical Instruments & Supplies company that operates in wider Healthcare sector, reached to the highest price of $19.01 whereas the lowest price it dropped to was $18.42. The 52-week range on BLCO shows that it touched its highest point at $19.96 and its lowest point at $12.20 during that stretch. It currently has a 1-year price target of $20.30.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BLCO was down-trending over the past week, with a drop of -4.66%, but this was up by 11.64% over a month. The stock gained 9.99% in the past year, while it has gained 19.92% so far this year. A look at the trailing 12-month EPS for BLCO yields -0.30 with Next year EPS estimates of 1.01. For the next quarter, that number is 0.14. This implies an EPS growth rate of -96.70% for this year and 28.86% for next year.

Float and Shares Shorts:

At present, 350.00 million BLCO shares are outstanding with a float of 349.08 million shares on hand for trading. On Apr 27, 2023, short shares totaled 6.47 million, which was 1.85% higher than short shares on Mar 30, 2023. In addition to Mr. Osama A. Eldessouky as the firm’s Exec. VP & CFO, Dr. Yehia Hashad M.D. serves as its Exec. VP of R&D and Chief Medical officer.

Institutional Ownership:

Through their ownership of 13.05% of BLCO’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 9.54% of BLCO, in contrast to 3.72% held by mutual funds. Shares owned by individuals account for 0.35%. As the largest shareholder in BLCO with 1.74% of the stake, GoldenTree Asset Management LP holds 6,102,426 shares worth 6,102,426. A second-largest stockholder of BLCO, Eminence Capital LP, holds 5,579,509 shares, controlling over 1.59% of the firm’s shares. Icahn Associates Holding LLC is the third largest shareholder in BLCO, holding 3,500,000 shares or 1.00% stake. With a 0.80% stake in BLCO, the Government Pension Fund – Global is the largest stakeholder. A total of 2,800,000 shares are owned by the mutual fund manager. The BlackRock Global Funds – World He, which owns about 0.55% of BLCO stock, is the second-largest Mutual Fund holder. It holds 1,936,495 shares valued at 33.81 million. Fidelity Canadian Opportunities F holds 0.43% of the stake in BLCO, owning 1,500,000 shares worth 26.19 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, BLCO reported revenue of $941.00M and operating income of $55.00M. The EBITDA in the recently reported quarter was $154.00M and diluted EPS was $0.01.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BLCO since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With BLCO analysts setting a high price target of $24.00 and a low target of $17.00, the average target price over the next 12 months is $20.33. Based on these targets, BLCO could surge 29.03% to reach the target high and fall by -8.6% to reach the target low. Reaching the average price target will result in a growth of 9.3% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.